Press Release

G2GBio has the best subject matter experts in the field of the injectable drug development.

G2GBIO confirms safety and tolerability of multiple doses for Alzheimer's drug candidate 'GB-5001' in Phase 1 clinical trial
2026.09.09
HIT 1009

G2GBIO confirms safety and tolerability of multiple doses for Alzheimer's drug candidate 'GB-5001' in Phase 1 clinical trial




- Drug concentration confirmed to reach ‘steady state’ after 3 to 4 administrations

- Daily oral ‘Donepezil’ replaced by a once-monthly injection – Poised to boost dementia medication adherence

 

 

 

[by Kang, In Hyo] G2GBIO announced in a public disclosure on August 27 that it has received the draft clinical study report (CSR) for the Phase 1 clinical trial of ‘GB-5001’ (development code), its long-acting dementia treatment candidate, confirming the drug’s safety and tolerability profile.

 

GB-5001 is a long-acting injectable candidate containing the active ingredient ‘donepezil,’ widely used worldwide to alleviate the symptoms of Alzheimer's disease (AD). Designed for once-monthly administration, the candidate addresses the inconvenience of existing oral formulations that must be taken daily and is expected to significantly reduce the treatment burden for patients with dementia who have difficulty swallowing tablets or frequently miss doses, as well as for their caregivers.

 

The Phase 1 trial evaluated the safety and tolerability of single and multiple doses of GB-5001. The results demonstrated a favorable safety profile, with no patients discontinuing treatment due to serious adverse events or other adverse reactions during the dosing period. In addition, repeated administration of GB-5001 140 mg at four-week intervals confirmed that ‘steady-state,’ when drug concentration in the body remain stable, was reached after three to four doses.

 

Notably, GB-5001 achieved a mean steady-state plasma concentration (Cavg, ss) comparable to that of the control group receiving oral Aricept 5 mg. Furthermore, its narrower fluctuation range between peak and trough concentrations demonstrated a more stable pharmacokinetic profile.

 

Professor Hong Jang-hee of Chungnam National University Hospital, who led the clinical trial, stated, “This study confirmed that GB-5001 was well tolerated and exhibited stable pharmacokinetic characteristics, including controlled initial release and sustained plasma concentrations for more than one month. As GB-5001 is being developed as a once-monthly formulation, we hope it will become a treatment option that eases the medication burden and inconvenience faced by patients and their caregivers.”

 

“This clinical trial has brought us one step closer to the commercialization of GB-5001. We will ensure that preparations for subsequent clinical trials proceed without any setbacks,” a G2GBIO official said.